Generic Crixivan Availability
CRIXIVAN (indinavir sulfate - capsule;oral)
Manufacturer: MERCK SHARP DOHME
Approval date: March 13, 1996
Strength(s): EQ 200MG BASE, EQ 400MG BASE [RLD]
Has a generic version of Crixivan been approved?
No. There is currently no therapeutically equivalent version of Crixivan available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Crixivan. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Dry granulation formulation for an HIV protease inhibitor
Issued: November 11, 2003
Inventor(s): Chung Y.; Lui & Drazen; Ostovic & Ashok V.; Katdare & Christine; Stelmach
Assignee(s): Merck & Co., Inc.
This invention relates to a dry granulation capsule formulation of the HIV protease inhibitor, indinavir sulfate, which is useful in the treatment of AIDS, ARC or HIV infection. Processes for making the oral formulation are also disclosed.Patent expiration dates:
- March 4, 2018✓
- March 4, 2018
Combination therapy for HIV infection
Issued: February 10, 2004
Inventor(s): Jeffrey A.; Chodakewitz & Emilio A.; Emini
Assignee(s): Merck & Co., Inc.
The combination of the HIV protease inhibitor Compound J, 3TC, and, optionally AZT, ddI, or ddC, is useful in the inhibition of HIV protease, the inhibition of HIV reverse transcriptase, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.Patent expiration dates:
- February 10, 2021✓
- February 10, 2021
- Crixivan Consumer Information (Wolters Kluwer)
- Crixivan Consumer Information (Cerner Multum)
- Crixivan Advanced Consumer Information (Micromedex®)
- Crixivan AHFS DI Monographs (ASHP)
- Indinavir Consumer Information (Wolters Kluwer)
- Indinavir Consumer Information (Cerner Multum)
- Indinavir Advanced Consumer Information (Micromedex®)
- Indinavir Sulfate AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|